January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 

Pipeline Three Icon Pipeline Three Header

Cambridge Healthtech Institute’s 8th Annual
Optimizing Biologics Formulation Development
Formulation Strategies for Different Stages of Development, New Product Formats,
Device/Delivery Systems and Emerging Analytical Methods

January 18-19, 2016

Each year, the PepTalk Optimizing Biologics Formulation Development meeting brings together an international audience of analytical and formulation scientists from leading industry companies to hear solutions to the most significant challenges in their field. For 2016, the conference focuses on formulation strategies in early and pre-commercial development, the challenges of new molecule and product formats, emerging technologies to support the speed and quality of formulation development, formulation issues for device and packaging systems and problem solving for the challenges in the day-to-day work of protein formulators.

Final Agenda

Day 1 | Day 2 | Download Brochure


SUNDAY, JANUARY 17


4:00-5:30 pm Registration

5:00-8:00 Dinner Short Courses


MONDAY, JANUARY 18

7:30 am Conference Registration and Morning Coffee

9:00 Chairperson’s Opening Remarks

Tarik Khan, Ph.D., Postdoctoral Fellow, Late-Stage Pharmaceutical and Processing Development, F. Hoffmann-La Roche Ltd.


KEYNOTE PRESENTATIONS

9:10 Formulation Strategies in an Era of Accelerating Timelines and Novel Biotherapeutic Modalities

Ping Y. YehPing Y. Yeh, Ph.D., Executive Director, Drug Product Formulation Technologies, Process Development, Amgen, Inc.

The advancement of bio-therapeutics to treat unmet medical needs has been progressively expanded to new disease targets. The “biology first and modality second” R&D strategy has been successfully applied to probe human biology, resulting in the engineering of novel protein modalities, many of which bring significant challenges to protein formulation and delivery. In this presentation, formulation strategy and technology considerations that bridge discovery and commercialization will be discussed.

9:45 Probing the Interface of Protein Stability Analysis, Formulation Development and Biosimilarity Assessments

David B. VolkinDavid B. Volkin, Takeru and Aya Higuchi Distinguished Professor, Pharmaceutical Chemistry, The University of Kansas School of Pharmacy

This presentation describes the challenges and opportunities of performing fingerprint analysis of various protein analysis data sets (e.g., higher-order structure, potency, pharmaceutical stability) and applying the results to formulation development and biosimilarity assessment. Topics include mathematical approaches to evaluate combined data sets from analysis of protein stability; applying these tools to a case study comparison of model, well-defined IgG1-Fc glycoforms; and potential future applications to fulllength mAbs and complex biomolecules.


10:20 Coffee Break


ANALYTICAL METHODS AND TECHNOLOGIES FOR FORMULATION DEVELOPMENT

10:45 Structure-Based Formulation Effects on Endotoxin Quantification

Tarik KhanTarik Khan, Ph.D., Postdoctoral Fellow, Late-Stage Pharmaceutical and Processing Development, F. Hoffmann-La Roche Ltd.

Parental pharmaceuticals must be monitored for the presence of toxic endotoxins, as they present a serious health hazard. The Limulus Amebocyte Lysate (LAL) assay has become the gold standard for analyzing drug product, but has recently been shown to loose sensitivity to controlled spike-ins in the presence of certain formulation buffers and surfactants. This talk will explore supramolecular endotoxin structure changes based on formulation conditions and their correlated LAL effects.

11:15 Biophysical Characterization of Peptide and Protein Formulations

Per-Olof WahlundPer-Olof Wahlund, Ph.D., Senior Scientist, Biophysics Screening & Characterization Novo Nordisk

Development of pharmaceutical formulations of peptides/proteins is a delicate balance between optimising pharmacological action, safety and stability. Extensive biophysical characterization is required to develop a stable formulation, by combining different biophysical methods it is possible to make a more complete interpretation and to generate crucial information regarding the peptide´s/protein´s solubility, self-association, and interactions with excipients. Illustrating case studies will be presented.

11:45 Integration of High Throughput Formulation Screening into Drug Product Development Process

Vladimir RazinkovVladimir Razinkov, Ph.D., Principal Scientist, Product Formulation Technologies, Amgen, Inc.

High throughput methods provide both speed and efficiency during selection of optimal formulation stability for biopharmaceutical product. It is critical to choose the right methods which are specific to modality and stage of development. High throughput screening methods are not only about fewer resources and faster processes. It is also about information-rich and comparable data suitable for statistical analysis allowing robust characterization and long term prediction of critical stability properties.

12:15 pm Case Stories of Protein and Peptide Stabilization Achieved by Co-Formulations with Recombinant Human Serum Albumin Derived from Baker’s Yeast

Jens Thostrup Bukrinski, Ph.D., Senior Scientist, Novozymes A/S, Biopharma R&D

An important property of albumin is the inherent ability to stabilize colloidal systems and albumin thus has a long history of use as a drug stabilizer. The mechanisms involved in the stabilization are multiple and dependent on the degradation pathway of the specific drug. One well-known mechanism is when albumin is used to coat hydrophobic and hydrophilic surfaces in packaging materials and process equipment preventing surface-induced aggregation and drug depletion. Mechanisms of stabilization for other degradation pathways are less well understood. New data indicating at least two different mechanisms is presented here. In some cases surface-exposed hydrophobic patches on albumin interact with problematic drug moieties forming a drug-albumin complex less prone to aggregate. In other cases, an excluded volume effect is observed and no drug-albumin complex observed.

12:45 Session Break

1:00 Luncheon Presentation I: A Novel Automated System for Buffer Exchange and Concentration of Biopharmaceuticals

Russell Burge, Ph.D., Applications Scientist, Freeslate Inc.

Protein formulation preparation requires either dilution or buffer exchange of a protein solution into multiple formulation buffers. Traditional approaches for buffer exchange include dialysis, desalting columns, and centrifugal UF/DF devices. While these are all relatively simple and easy, they are also manual, and specifically dialysis and desalting columns do not allow for protein concentration. Recently, Freeslate has developed a novel automated system for efficient buffer exchange and concentration of biopharmaceuticals. In this talk, we describe this system and its application to protein formulation preparation.

1:30 Luncheon Presentation II (Sponsorship Opportunity Available)


FORMULATION SOLUTIONS FOR NOVEL BIOTHERAPEUTICS

2:00 Chairperson’s Remarks

Valentyn Antochshuk, Ph.D., Principal Scientist, Bioprocess Development, Merck

2:05 Characterization of Stability and Small Molecule Related Species in Antibody Drug Conjugates

Colin MedleyColin Medley, Ph.D., Scientist, Genentech, Inc.

Antibody drug conjugates (ADCs) are complex therapeutic agents combining the specific targeting properties of antibodies and highly potent cytotoxic small molecule. One critical quality attribute of ADCs is the purity and stability of the active drug on the ADC, which is difficult to access once the drug is conjugated to the antibody. This talk will highlight some of ways we’re evaluating the small molecule portion of ADCs.

2:35 Factors Impacting the Stability of Multi-Domain Fusion Proteins

Roberto DePazRoberto DePaz, Ph.D., Senior Scientist, Biopharmaceutical Development, MedImmune

Fusion proteins are a class of biopharmaceuticals engineered for longer half-life and multiple specificities. These multi-domain proteins may lack stabilizing interdomain interactions, complicating formulation development. The conformational and colloidal stability of a fusion protein and the individual domains each contribute to overall physical stability. Formulation considerations for fusion proteins will be discussed, including instances where the relative importance of conformational and colloidal stability varies depending on solution conditions.

3:05 Overcoming Formulation and Analytical Development Challenges for Novel Bispecific BEAT® Format

Julie BonvinJulie Bonvin, Ph.D., Lead, Analytical Development Group, Glenmark Pharmaceuticals

Glenmark’s novel bispecific format (scFv-Fab BEAT®) has opened the possibilities of providing a highly efficient treatment of cancer. The format is a fusion of a Fab and a scFv, where scFv arm binds to the target while Fab binds to T-cells, thereby redirecting T-cells to kill tumor cells. Little is known about our novel mAb formats and the presentation will address the issue by providing novel, relevant and contemporary data.

3:35 Presentation to be Announced



3:50 Refreshment Break in the Exhibit Hall with Poster Viewing

4:30 Challenges in the Development of a Formulation for Monoclonal Antibody Mixtures in the Treatment of Botulism

Susan BabukaSusan Babuka, Senior Formulation Scientist, XOMA Corp.

XOMA is developing monoclonal antibody-based drug products for the treatment of botulism. Each serotype-specific drug product comprises a mixture of at least three monoclonal antibodies. Formulation of each drug product requires balancing multiple degradation mechanisms to reach a common stability target and ultimately achieve a stability optimum. To illustrate the process utilized in formulation development, sample data showing stability analysis, degradation mechanisms and resulting impurities are provided.

5:00 Predictive Modeling to Support Early Stage Formulation Stability Analysis for Vaccines and Biologics

Manvi Hasija, MBT, Stability Scientist, BRD, Sanofi Pasteur


5:45 BuzZ Session A

Join your peers and colleagues for interactive roundtable discussions.

6:30-7:45 Welcome Reception in the Exhibit Hall with Poster Viewing

7:45 Close of Day

Day 1 | Day 2 | Download Brochure

TUESDAY, JANUARY 19

8:00 am Conference Registration and Morning Coffee


STRATEGIES FOR THE STAGES OF FORMULATION DEVELOPMENT

8:30 Chairperson’s Remarks

Hardeep Samra, Ph.D., Senior Scientist, Formulation Sciences, MedImmune

8:35 Bioanalytical Tools for Developability Evaluation

Valentyn AntochshukValentyn Antochshuk, Ph.D., Principal Scientist, Bioprocess Development, Merck

Successful product and process development is heavily dependent on the understanding of molecular properties and liabilities. Choice of analytical tools and stress conditions is critical for product attributes assessment, speed of development, data understanding, connection between preformulation/developability and formulation/process development. Implementation of high throughput and stage appropriate biophysical and biochemical toolbox accelerates feedback on candidate selection, program de-risking and successful pharmaceutical development.

9:05 Considerations and Approaches for Late Stage Formulation Characterization of Biologics

Hardeep SamraHardeep Samra, Ph.D., Senior Scientist, Formulation Sciences, MedImmune

 


 

 

9:35 Sponsored Presentation (Opportunity Available)

9:50 Coffee Break in the Exhibit Hall with Poster Viewing


DELIVERY AND DEVICES

11:00 Formulation Considerations for Developing a High Concentration Biologics Product in Multiple Presentations

Kapil Gupta, Ph.D., Principal Scientist and Group Leader, Protein Drug Product and Device Development, Biogen

Many biologics products are developed as combination products in multiple final market image for different patient population, dosing regimen and geography. This brings in tremendous complexity for formulation and drug product development as parallel development need to happen for many presentations using creative bracketing and risk mitigation strategy. This talk highlights some of the challenges of developing a high concentration biologic product in multiple presentations and potential strategies to overcome them.

11:30 Integrating Design Controls in Formulation Development for Combination Products

Ling LuLing Lu, Senior Principal Scientist, Design Controls, Pharmaceutical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer, Inc.

There are challenges for formulators when developing combination products per Final Rule. This case study will explain: 1) Streamlined process with value added design control activities per Final Rule and FDA draft guidance; and 2) Three kinds of combination products, and design controls based on complexities and risks of products, comparing early phases in clinical and market application, professional and home use.

12:00 pm Presentation to be Announced

12:30 Session Break

12:45 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:45 Close of Conference


Day 1 | Day 2 | Download Brochure